Corrigendum to “Genetics of Parkinson's disease” [Mol. Cell. Probes (2016) 386–396](S0890850816301037)(10.1016/j.mcp.2016.11.001);Genetics of Parkinson's disease

Molecular and Cellular Probes

Volumn 30, Issue 6, 2016, Pages 386-396

  Lill, Christina M ^a  

^a UNIVERSITY OF LÜBECK   (Germany)

Author keywords

Environment; Epidemiology; Genetic association; Genetic risk score; Genome wide association study; GWAS; Interaction; Parkinson's disease; Prediction

Indexed keywords

AUTOSOMAL DOMINANT INHERITANCE; AUTOSOMAL RECESSIVE INHERITANCE; DNAJC6 GENE; EPIGENETICS; EXOME; GENE; GENE MUTATION; GENE SEQUENCE; GENETIC RISK; GENETIC VARIABILITY; GENOME-WIDE ASSOCIATION STUDY; GENOTYPE ENVIRONMENT INTERACTION; HEREDITY; HUMAN; LRRK2 GENE; NONHUMAN; PARKIN GENE; PARKINSON DISEASE; PENETRANCE; PINK1 GENE; PRIORITY JOURNAL; REVIEW; SNCA GENE; VPS35 GENE; GENETIC ASSOCIATION STUDY; GENETIC PREDISPOSITION; GENETICS; PROCEDURES; RISK FACTOR; SINGLE NUCLEOTIDE POLYMORPHISM;

ALPHA SYNUCLEIN; PARKIN; SNCA PROTEIN, HUMAN; UBIQUITIN PROTEIN LIGASE;

ALPHA-SYNUCLEIN; GENE-ENVIRONMENT INTERACTION; GENETIC ASSOCIATION STUDIES; GENETIC PREDISPOSITION TO DISEASE; GENOME-WIDE ASSOCIATION STUDY; HUMANS; PARKINSON DISEASE; POLYMORPHISM, SINGLE NUCLEOTIDE; RISK FACTORS; UBIQUITIN-PROTEIN LIGASES;

EID: 84997497966     PISSN: 08908508     EISSN: 10961194     Source Type: Journal    
DOI: 10.1016/j.mcp.2020.101537     Document Type: Erratum

References (144)

1. [1] de Lau, L.M.L., Breteler, M.M.B., Epidemiology of Parkinson's disease. Lancet Neurol. 5:6 (2006 Jun), 525–535.
2. [2] Dorsey, E.R., Constantinescu, R., Thompson, J.P., Biglan, K.M., Holloway, R.G., Kieburtz, K., et al. Projected number of people with Parkinson disease in the most populous nations, 2005 through 2030. Neurology 68:5 (2007 Jan 30), 384–386.
3. [3] Lewy, F.H., Paralysis agitans: pathologische Anatomie. Lewandowski, M., (eds.) Handbuch der Neurologie, 1912, Springer, Berlin, 920–933.
4. [4] Spillantini, M.G., Schmidt, M.L., Lee, V.M., Trojanowski, J.Q., Jakes, R., Goedert, M., Alpha-synuclein in Lewy bodies. Nature 388:6645 (1997 Aug 28), 839–840.
5. [5] Braak, H., Del Tredici, K., Rüb, U., de Vos, R.A.I., Jansen Steur, E.N.H., Braak, E., Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol. Aging 24:2 (2003 Apr), 197–211.
6. [6] Houlden, H., Singleton, A.B., The genetics and neuropathology of Parkinson's disease. Acta Neuropathol. 124:3 (2012 Sep), 325–338.
7. [7] Hughes, A.J., Daniel, S.E., Kilford, L., Lees, A.J., Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases. J. Neurol. Neurosurg. Psychiatr. 55:3 (1992 Mar), 181–184.
8. [8] Gelb, D.J., Oliver, E., Gilman, S., Diagnostic criteria for Parkinson disease. Arch. Neurol. 56:1 (1999 Jan), 33–39.
9. [9] Jellinger, K.A., A critical reappraisal of current staging of Lewy-related pathology in human brain. Acta Neuropathol. 116:1 (2008 Jul), 1–16.
10. [10] Beach, T.G., Adler, C.H., Lue, L., Sue, L.I., Bachalakuri, J., Henry-Watson, J., et al. Unified staging system for Lewy body disorders: correlation with nigrostriatal degeneration, cognitive impairment and motor dysfunction. Acta Neuropathol. 117:6 (2009 Jun), 613–634.
11. [11] Schrag, A., Horsfall, L., Walters, K., Noyce, A., Petersen, I., Prediagnostic presentations of Parkinson's disease in primary care: a case-control study. Lancet Neurol. 14:1 (2015 Jan), 57–64.
12. [12] Saarni, S.I., Härkänen, T., Sintonen, H., Suvisaari, J., Koskinen, S., Aromaa, A., et al. The impact of 29 chronic conditions on health-related quality of life: a general population survey in Finland using 15D and EQ-5D. Qual. Life Res. 15:8 (2006 Oct), 1403–1414.
13. [13] Goetz, C.G., Pal, G., Initial management of Parkinson's disease. BMJ, 349, 2014, g6258.
14. [14] Cheng, H.-C., Ulane, C.M., Burke, R.E., Clinical progression in Parkinson disease and the neurobiology of axons. Ann. Neurol. 67:6 (2010 Jun), 715–725.
15. [15] AlDakheel, A., Kalia, L.V., Lang, A.E., Pathogenesis-targeted, disease-modifying therapies in Parkinson disease. Neurotherapeutics 11:1 (2014 Jan), 6–23.
16. [16] Bell, J., Clark, A.J., A pedigree of paralysis agitans. Ann. Eugen. 1 (1926), 455–462.
17. [17] Allan, W., Inheritance of shaking pals. Arch. Intern Med. 60 (1937), 424–436.
18. [18] Lazzarini, A.M., Myers, R.H., Zimmerman, T.R., Mark, M.H., Golbe, L.I., Sage, J.I., et al. A clinical genetic study of Parkinson's disease: evidence for dominant transmission. Neurology 44:3 Pt 1 (1994 Mar), 499–506.
19. [19] Bonifati, V., Fabrizio, E., Vanacore, N., De Mari, M., Meco, G., Familial Parkinson's disease: a clinical genetic analysis. Can. J. Neurol. Sci. 22:4 (1995 Nov), 272–279.
20. [20] Lill, C.M., Mashychev, A., Hartmann, C., Lohmann, K., Marras, C., Lang, A.E., et al. Launching the movement disorders society genetic mutation database (MDSGene). Mov. Disord. 31:5 (2016 May), 607–609.
21. [21] Nalls, M.A., Pankratz, N., Lill, C.M., Do, C.B., Hernandez, D.G., Saad, M., et al. Large-scale meta-analysis of genome-wide association data identifies six new risk loci for Parkinson's disease. Nat. Genet. 46:9 (2014 Sep), 989–993.
22. [22] Lill, C.M., Roehr, J.T., McQueen, M.B., Kavvoura, F.K., Bagade, S., Schjeide, B.-M.M., et al. Comprehensive research synopsis and systematic meta-analyses in Parkinson's disease genetics: the PDGene database. PLoS Genet., 8(3), 2012, e1002548.
23. [23] Polymeropoulos, M.H., Lavedan, C., Leroy, E., Ide, S.E., Dehejia, A., Dutra, A., et al. Mutation in the alpha-synuclein gene identified in families with Parkinson's disease. Science 276:5321 (1997 Jun 27), 2045–2047.
24. [24] Krüger, R., Kuhn, W., Müller, T., Woitalla, D., Graeber, M., Kösel, S., et al. Ala30Pro mutation in the gene encoding alpha-synuclein in Parkinson's disease. Nat. Genet. 18:2 (1998 Feb), 106–108.
25. [25] Zarranz, J.J., Alegre, J., Gómez-Esteban, J.C., Lezcano, E., Ros, R., Ampuero, I., et al. The new mutation, E46K, of alpha-synuclein causes Parkinson and Lewy body dementia. Ann. Neurol. 55:2 (2004 Feb), 164–173.
26. [26] Lesage, S., Anheim, M., Letournel, F., Bousset, L., Honoré, A., Rozas, N., et al. G51D α-synuclein mutation causes a novel parkinsonian-pyramidal syndrome. Ann. Neurol. 73:4 (2013 Apr), 459–471.
27. [27] Kiely, A.P., Asi, Y.T., Kara, E., Limousin, P., Ling, H., Lewis, P., et al. α-Synucleinopathy associated with G51D SNCA mutation: a link between Parkinson's disease and multiple system atrophy?. Acta Neuropathol. 125:5 (2013 May), 753–769.
28. [28] Appel-Cresswell, S., Vilarino-Guell, C., Encarnacion, M., Sherman, H., Yu, I., Shah, B., et al. Alpha-synuclein p.H50Q, a novel pathogenic mutation for Parkinson's disease. Mov. Disord. 28:6 (2013 Jun), 811–813.
29. [29] Proukakis, C., Dudzik, C.G., Brier, T., MacKay, D.S., Cooper, J.M., Millhauser, G.L., et al. A novel α-synuclein missense mutation in Parkinson disease. Neurology 80:11 (2013 Mar 12), 1062–1064.
30. [30] Chartier-Harlin, M.-C., Kachergus, J., Roumier, C., Mouroux, V., Douay, X., Lincoln, S., et al. Alpha-synuclein locus duplication as a cause of familial Parkinson's disease. Lancet 364:9440 (2004 Oct 25), 1167–1169.
31. [31] Ibáñez, P., Bonnet, A.-M., Débarges, B., Lohmann, E., Tison, F., Pollak, P., et al. Causal relation between alpha-synuclein gene duplication and familial Parkinson's disease. Lancet 364:9440 (2004 Oct 25), 1169–1171.
32. [32] Singleton, A.B., Farrer, M., Johnson, J., Singleton, A., Hague, S., Kachergus, J., et al. alpha-Synuclein locus triplication causes Parkinson's disease. Science, 302(5646), 2003 Oct 31, 841.
33. [33] Bendor, J.T., Logan, T.P., Edwards, R.H., The function of α-synuclein. Neuron 79:6 (2013 Sep 18), 1044–1066.
34. [34] Lill, C.M., Bertram, L., Towards unveiling the genetics of neurodegenerative diseases. Semin. Neurol. 31:5 (2011 Nov), 531–541.
35. [35] Brettschneider, J., Del Tredici, K., Lee, V.M.-Y., Trojanowski, J.Q., Spreading of pathology in neurodegenerative diseases: a focus on human studies. Nat. Rev. Neurosci. 16:2 (2015 Feb), 109–120.
36. [36] Walsh, D.M., Selkoe, D.J., A critical appraisal of the pathogenic protein spread hypothesis of neurodegeneration. Nat. Rev. Neurosci. 17:4 (2016 Mar 18), 251–260.
37. [37] Zimprich, A., Biskup, S., Leitner, P., Lichtner, P., Farrer, M., Lincoln, S., et al. Mutations in LRRK2 cause autosomal-dominant parkinsonism with pleomorphic pathology. Neuron 44:4 (2004 Nov 18), 601–607.
38. [38] Paisán-Ruíz, C., Jain, S., Evans, E.W., Gilks, W.P., Simón, J., van der Brug, M., et al. Cloning of the gene containing mutations that cause PARK8-linked Parkinson's disease. Neuron 44:4 (2004 Nov 18), 595–600.
39. [39] Healy, D.G., Falchi, M., O'Sullivan, S.S., Bonifati, V., Durr, A., Bressman, S., et al. Phenotype, genotype, and worldwide genetic penetrance of LRRK2-associated Parkinson's disease: a case-control study. Lancet Neurol. 7:7 (2008 Jul), 583–590.
40. [40] Ross, O.A., Soto-Ortolaza, A.I., Heckman, M.G., Aasly, J.O., Abahuni, N., Annesi, G., et al. Association of LRRK2 exonic variants with susceptibility to Parkinson's disease: a case-control study. Lancet Neurol. 10:10 (2011 Oct), 898–908.
41. [41] Trinh, J., Guella, I., McKenzie, M., Gustavsson, E.K., Szu-Tu, C., Petersen, M.S., et al. Novel LRRK2 mutations in parkinsonism. Park. Relat. Disord. 21:9 (2015 Sep), 1119–1121.
42. [42] Webber, P.J., West, A.B., LRRK2 in Parkinson's disease: function in cells and neurodegeneration. FEBS J. 276:22 (2009 Nov), 6436–6444.
43. [43] Steger, M., Tonelli, F., Ito, G., Davies, P., Trost, M., Vetter, M., et al. Phosphoproteomics reveals that Parkinson's disease kinase LRRK2 regulates a subset of Rab GTPases. Elife, 2016, 5.
44. [44] Zimprich, A., Benet-Pagès, A., Struhal, W., Graf, E., Eck, S.H., Offman, M.N., et al. A mutation in VPS35, encoding a subunit of the retromer complex, causes late-onset Parkinson disease. Am. J. Hum. Genet. 89:1 (2011 Jul 15), 168–175.
45. [45] Vilariño-Güell, C., Wider, C., Ross, O.A., Dachsel, J.C., Kachergus, J.M., Lincoln, S.J., et al. VPS35 mutations in Parkinson disease. Am. J. Hum. Genet. 89:1 (2011 Jul 15), 162–167.
46. [46] Sharma, M., Ioannidis, J.P.A., Aasly, J.O., Annesi, G., Brice, A., Bertram, L., et al. A multi-centre clinico-genetic analysis of the VPS35 gene in Parkinson disease indicates reduced penetrance for disease-associated variants. J. Med. Genet. 49:11 (2012 Nov), 721–726.
47. [47] Trinh, J., Farrer, M., Advances in the genetics of Parkinson disease. Nat. Rev. Neurol. 9:8 (2013 Aug), 445–454.
48. [48] Kitada, T., Asakawa, S., Hattori, N., Matsumine, H., Yamamura, Y., Minoshima, S., et al. Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism. Nature 392:6676 (1998 Apr 9), 605–608.
49. [49] Valente, E.M., Abou-Sleiman, P.M., Caputo, V., Muqit, M.M.K., Harvey, K., Gispert, S., et al. Hereditary early-onset Parkinson's disease caused by mutations in PINK1. Science 304:5674 (2004 May 21), 1158–1160.
50. [50] Bonifati, V., Rizzu, P., van Baren, M.J., Schaap, O., Breedveld, G.J., Krieger, E., et al. Mutations in the DJ-1 gene associated with autosomal recessive early-onset parkinsonism. Science 299:5604 (2003 Jan 10), 256–259.
51. [51] Kilarski, L.L., Pearson, J.P., Newsway, V., Majounie, E., Knipe, M.D.W., Misbahuddin, A., et al. Systematic review and UK-based study of PARK2 (parkin), PINK1, PARK7 (DJ-1) and LRRK2 in early-onset Parkinson's disease. Mov. Disord. 27:12 (2012 Oct), 1522–1529.
52. [52] Abbas, N., Lücking, C.B., Ricard, S., Dürr, A., Bonifati, V., De Michele, G., et al. A wide variety of mutations in the parkin gene are responsible for autosomal recessive parkinsonism in Europe. French Parkinson's Disease Genetics Study Group and the European Consortium on Genetic Susceptibility in Parkinson's Disease. Hum. Mol. Genet. 8:4 (1999 Apr), 567–574.
53. [53] Hedrich, K., Eskelson, C., Wilmot, B., Marder, K., Harris, J., Garrels, J., et al. Distribution, type, and origin of Parkin mutations: review and case studies. Mov. Disord. 19:10 (2004 Oct), 1146–1157.
54. [54] Fitzgerald, J.C., Plun-Favreau, H., Emerging pathways in genetic Parkinson's disease: autosomal-recessive genes in Parkinson's disease–a common pathway?. FEBS J. 275:23 (2008 Dec), 5758–5766.
55. [55] Narendra, D., Walker, J.E., Youle, R., Mitochondrial quality control mediated by PINK1 and Parkin: links to parkinsonism. Cold Spring Harb. Perspect. Biol., 4(11), 2012 Nov.
56. [56] Kim, R.H., Smith, P.D., Aleyasin, H., Hayley, S., Mount, M.P., Pownall, S., et al. Hypersensitivity of DJ-1-deficient mice to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyrindine (MPTP) and oxidative stress. Proc. Natl. Acad. Sci. U. S. A. 102:14 (2005 Apr 5), 5215–5220.
57. [57] Edvardson, S., Cinnamon, Y., Ta-Shma, A., Shaag, A., Yim, Y.-I., Zenvirt, S., et al. A deleterious mutation in DNAJC6 encoding the neuronal-specific clathrin-uncoating co-chaperone auxilin, is associated with juvenile parkinsonism. PLoS One, 7(5), 2012, e36458.
58. [58] Köroğlu, Ç., Baysal, L., Cetinkaya, M., Karasoy, H., Tolun, A., DNAJC6 is responsible for juvenile parkinsonism with phenotypic variability. Park. Relat. Disord. 19:3 (2013 Mar), 320–324.
59. [59] Olgiati, S., Quadri, M., Fang, M., Rood, J.P.M.A., Saute, J.A., Chien, H.F., et al. DNAJC6 mutations associated with early-onset Parkinson's disease. Ann. Neurol. 79:2 (2016 Feb), 244–256.
60. [60] Elsayed, L.E.O., Drouet, V., Usenko, T., Mohammed, I.N., Hamed, A.A.A., Elseed, M.A., et al. A novel nonsense mutation in DNAJC6 expands the phenotype of autosomal-recessive juvenile-onset Parkinson's disease. Ann. Neurol. 79:2 (2016 Feb), 335–337.
61. [61] Eisenberg, E., Greene, L.E., Multiple roles of auxilin and hsc70 in clathrin-mediated endocytosis. Traffic 8:6 (2007 Jun), 640–646.
62. [62] Ramirez, A., Heimbach, A., Gründemann, J., Stiller, B., Hampshire, D., Cid, L.P., et al. Hereditary parkinsonism with dementia is caused by mutations in ATP13A2, encoding a lysosomal type 5 P-type ATPase. Nat. Genet. 38:10 (2006 Oct), 1184–1191.
63. [63] Park, J.-S., Blair, N.F., Sue, C.M., The role of ATP13A2 in Parkinson's disease: clinical phenotypes and molecular mechanisms. Mov. Disord. 30:6 (2015 May), 770–779.
64. [64] Shojaee, S., Sina, F., Banihosseini, S.S., Kazemi, M.H., Kalhor, R., Shahidi, G.-A., et al. Genome-wide linkage analysis of a Parkinsonian-pyramidal syndrome pedigree by 500 K SNP arrays. Am. J. Hum. Genet. 82:6 (2008 Jun), 1375–1384.
65. [65] Paisan-Ruiz, C., Bhatia, K.P., Li, A., Hernandez, D., Davis, M., Wood, N.W., et al. Characterization of PLA2G6 as a locus for dystonia-parkinsonism. Ann. Neurol. 65:1 (2009 Jan), 19–23.
66. [66] Krebs, C.E., Karkheiran, S., Powell, J.C., Cao, M., Makarov, V., Darvish, H., et al. The Sac1 domain of SYNJ1 identified mutated in a family with early-onset progressive Parkinsonism with generalized seizures. Hum. Mutat. 34:9 (2013 Sep), 1200–1207.
67. [67] Quadri, M., Fang, M., Picillo, M., Olgiati, S., Breedveld, G.J., Graafland, J., et al. Mutation in the SYNJ1 gene associated with autosomal recessive, early-onset Parkinsonism. Hum. Mutat. 34:9 (2013 Sep), 1208–1215.
68. [68] Lohmann, E., Coquel, A.-S., Honoré, A., Gurvit, H., Hanagasi, H., Emre, M., et al. A new F-box protein 7 gene mutation causing typical Parkinson's disease. Mov. Disord. 30:8 (2015 Jul), 1130–1133.
69. [69] Marras, C., Lang, A., van de Warrenburg, B.P., Sue, C., Tabrizi, S.J., Bertram, L., et al. Nomenclature of genetic movement disorders: recommendations of the international parkinson and movement disorder society task force. Mov. Disord. 31:4 (2016 Apr), 436–457.
70. [70] Vilariño-Güell, C., Rajput, A., Milnerwood, A.J., Shah, B., Szu-Tu, C., Trinh, J., et al. DNAJC13 mutations in Parkinson disease. Hum. Mol. Genet. 23:7 (2014 Apr 1), 1794–1801.
71. [71] Funayama, M., Ohe, K., Amo, T., Furuya, N., Yamaguchi, J., Saiki, S., et al. CHCHD2 mutations in autosomal dominant late-onset Parkinson's disease: a genome-wide linkage and sequencing study. Lancet Neurol. 14:3 (2015 Mar), 274–282.
72. [72] Deng, H.-X., Shi, Y., Yang, Y., Ahmeti, K.B., Miller, N., Huang, C., et al. Identification of TMEM230 mutations in familial Parkinson's disease. Nat. Genet. 48:7 (2016 Jul), 733–739.
73. [73] Lesage, S., Drouet, V., Majounie, E., Deramecourt, V., Jacoupy, M., Nicolas, A., et al. Loss of VPS13C function in autosomal-recessive parkinsonism causes mitochondrial dysfunction and increases PINK1/Parkin-Dependent Mitophagy. Am. J. Hum. Genet. 98:3 (2016 Mar 3), 500–513.
74. [74] Wilson, G.R., Sim, J.C.H., McLean, C., Giannandrea, M., Galea, C.A., Riseley, J.R., et al. Mutations in RAB39B cause X-linked intellectual disability and early-onset Parkinson disease with α-synuclein pathology. Am. J. Hum. Genet. 95:6 (2014 Dec 4), 729–735.
75. [75] Farlow, J.L., Robak, L.A., Hetrick, K., Bowling, K., Boerwinkle, E., Coban-Akdemir, Z.H., et al. Whole-exome sequencing in familial Parkinson Disease. JAMA Neurol. 73:1 (2016 Jan 1), 68–75.
76. [76] Foo, J.N., Liany, H., Tan, L.C., Au, W.-L., Prakash, K.-M., Liu, J., et al. DNAJ mutations are rare in Chinese Parkinson's disease patients and controls. Neurobiol. Aging, 35(4), 2014 Apr, 935 e1–2.
77. [77] Lorenzo-Betancor, O., Ogaki, K., Soto-Ortolaza, A.I., Labbe, C., Walton, R.L., Strongosky, A.J., et al. DNAJC13 p.Asn855Ser mutation screening in Parkinson's disease and pathologically confirmed Lewy body disease patients. Eur. J. Neurol. 22:9 (2015 Sep), 1323–1325.
78. [78] Ross, J.P., Dupre, N., Dauvilliers, Y., Strong, S., Ambalavanan, A., Spiegelman, D., et al. Analysis of DNAJC13 mutations in French-Canadian/French cohort of Parkinson's disease. Neurobiol. Aging, 45, 2016 Sep, 212 e13–7.
79. [79] Liu, Z., Guo, J., Li, K., Qin, L., Kang, J., Shu, L., et al. Mutation analysis of CHCHD2 gene in Chinese familial Parkinson's disease. Neurobiol. Aging, 36(11), 2015 Nov, 3117 e7–8.
80. [80] Zhang, M., Xi, Z., Fang, S., Ghani, M., Sato, C., Moreno, D., et al. Mutation analysis of CHCHD2 in Canadian patients with familial Parkinson's disease. Neurobiol. Aging, 38, 2016 Feb, 217 e7–8.
81. [81] Fan, T.-S., Lin, H.-I., Lin, C.-H., Wu, R.-M., Lack of CHCHD2 mutations in Parkinson's disease in a Taiwanese population. Neurobiol. Aging, 38, 2016 Feb, 218 e1–2.
82. [82] Li, N.-N., Wang, L., Tan, E.-K., Cheng, L., Sun, X.-Y., Lu, Z.-J., et al. Genetic analysis of CHCHD2 gene in Chinese Parkinson's disease. Am. J. Med. Genet. B Neuropsychiatr. Genet., 2016 Sep 14.
83. [83] Löchte, T., Brüggemann, N., Vollstedt, E.-J., Krause, P., Domingo, A., Rosales, R., et al. RAB39B mutations are a rare finding in Parkinson disease patients. Park. Relat. Disord. 23 (2016 Feb), 116–117.
84. [84] Yuan, L., Deng, X., Song, Z., Yang, Z., Ni, B., Chen, Y., et al. Genetic analysis of the RAB39B gene in Chinese Han patients with Parkinson's disease. Neurobiol. Aging, 36(10), 2015 Oct, 2907 e11–2.
85. [85] Hodges, K., Brewer, S.S., Labbé, C., Soto-Ortolaza, A.I., Walton, R.L., Strongosky, A.J., et al. RAB39B gene mutations are not a common cause of Parkinson's disease or dementia with Lewy bodies. Neurobiol. Aging 45 (2016 Sep), 107–108.
86. [86] Chartier-Harlin, M.-C., Dachsel, J.C., Vilariño-Güell, C., Lincoln, S.J., Leprêtre, F., Hulihan, M.M., et al. Translation initiator EIF4G1 mutations in familial Parkinson disease. Am. J. Hum. Genet. 89:3 (2011 Sep 9), 398–406.
87. [87] Huttenlocher, J., Krüger, R., Capetian, P., Lohmann, K., Brockmann, K., Csoti, I., et al. EIF4G1 is neither a strong nor a common risk factor for Parkinson's disease: evidence from large European cohorts. J. Med. Genet. 52:1 (2015 Jan), 37–41.
88. [88] Nichols, N., Bras, J.M., Hernandez, D.G., Jansen, I.E., Lesage, S., Lubbe, S., et al. EIF4G1 mutations do not cause Parkinson's disease. Neurobiol. Aging, 36(8), 2015 Aug, 2444 e1–4.
89. [89] Mencacci, N.E., Isaias, I.U., Reich, M.M., Ganos, C., Plagnol, V., Polke, J.M., et al. Parkinson's disease in GTP cyclohydrolase 1 mutation carriers. Brain 137:Pt 9 (2014 Sep), 2480–2492.
90. [90] Tadic, V., Kasten, M., Brüggemann, N., Stiller, S., Hagenah, J., Klein, C., Dopa-responsive dystonia revisited: diagnostic delay, residual signs, and nonmotor signs. Arch. Neurol. 69:12 (2012 Dec), 1558–1562.
91. [91] Weissbach, A., Klein, C., Hereditary dystonia and parkinsonism: two sides of the same coin?. Brain 137:Pt 9 (2014 Sep), 2402–2404.
92. [92] Lill, C.M., Klein, C., Chapt. 1: the neurogenetics of Parkinson's disease and putative links to other neurodegenerative disorders. Verstreken, Patrik, (eds.) Parkinson's Disease, 2016, Elsevier, Inc in press.
93. [93] Krüger, R., Vieira-Saecker, A.M., Kuhn, W., Berg, D., Müller, T., Kühnl, N., et al. Increased susceptibility to sporadic Parkinson's disease by a certain combined alpha-synuclein/apolipoprotein E genotype. Ann. Neurol. 45:5 (1999 May), 611–617.
94. [94] Skipper, L., Li, Y., Bonnard, C., Pavanni, R., Yih, Y., Chua, E., et al. Comprehensive evaluation of common genetic variation within LRRK2 reveals evidence for association with sporadic Parkinson's disease. Hum. Mol. Genet. 14:23 (2005 Dec 1), 3549–3556.
95. [95] Paisán-Ruíz, C., Lang, A.E., Kawarai, T., Sato, C., Salehi-Rad, S., Fisman, G.K., et al. LRRK2 gene in Parkinson disease: mutation analysis and case control association study. Neurology 65:5 (2005 Sep 13), 696–700.
96. [96] Biskup, S., Mueller, J.C., Sharma, M., Lichtner, P., Zimprich, A., Berg, D., et al. Common variants of LRRK2 are not associated with sporadic Parkinson's disease. Ann. Neurol. 58:6 (2005 Dec), 905–908.
97. [97] Maraganore, D.M., de Andrade, M., Elbaz, A., Farrer, M.J., Ioannidis, J.P., Krüger, R., et al. Collaborative analysis of alpha-synuclein gene promoter variability and Parkinson disease. JAMA 296:6 (2006 Aug 9), 661–670.
98. [98] Pihlstrøm L, Lill CM, Hansen J, Bjørnarå KA, Dizdar N, Fardell C, et al. Allelic heterogeneity and risk stratification at the SNCA locus in Parkinson's disease. in preparation;.
99. [99] Di Fonzo, A., Wu-Chou, Y.-H., Lu, C.-S., van Doeselaar, M., Simons, E.J., Rohé, C.F., et al. A common missense variant in the LRRK2 gene, Gly2385Arg, associated with Parkinson's disease risk in Taiwan. Neurogenetics 7:3 (2006 Jul), 133–138.
100. [100] Morris, H.R., Janssen, J.C., Bandmann, O., Daniel, S.E., Rossor, M.N., Lees, A.J., et al. The tau gene A0 polymorphism in progressive supranuclear palsy and related neurodegenerative diseases. J. Neurol. Neurosurg. Psychiatr. 66:5 (1999 May), 665–667.
101. [101] Golbe, L.I., Lazzarini, A.M., Spychala, J.R., Johnson, W.G., Stenroos, E.S., Mark, M.H., et al. The tau A0 allele in Parkinson's disease. Mov. Disord. 16:3 (2001 May), 442–447.
102. [102] Maraganore, D.M., Hernandez, D.G., Singleton, A.B., Farrer, M.J., McDonnell, S.K., Hutton, M.L., et al. Case-Control study of the extended tau gene haplotype in Parkinson's disease. Ann. Neurol. 50:5 (2001 Nov), 658–661.
103. [103] Martin, E.R., Scott, W.K., Nance, M.A., Watts, R.L., Hubble, J.P., Koller, W.C., et al. Association of single-nucleotide polymorphisms of the tau gene with late-onset Parkinson disease. JAMA 286:18 (2001 Nov 14), 2245–2250.
104. [104] Stefansson, H., Helgason, A., Thorleifsson, G., Steinthorsdottir, V., Masson, G., Barnard, J., et al. A common inversion under selection in Europeans. Nat. Genet. 37:2 (2005 Feb), 129–137.
105. [105] Satake, W., Nakabayashi, Y., Mizuta, I., Hirota, Y., Ito, C., Kubo, M., et al. Genome-wide association study identifies common variants at four loci as genetic risk factors for Parkinson's disease. Nat. Genet. 41:12 (2009 Dec), 1303–1307.
106. [106] Höglinger, G.U., Melhem, N.M., Dickson, D.W., Sleiman, P.M.A., Wang, L.-S., Klei, L., et al. Identification of common variants influencing risk of the tauopathy progressive supranuclear palsy. Nat. Genet. 43:7 (2011 Jul), 699–705.
107. [107] Kouri, N., Ross, O.A., Dombroski, B., Younkin, C.S., Serie, D.J., Soto-Ortolaza, A., et al. Genome-wide association study of corticobasal degeneration identifies risk variants shared with progressive supranuclear palsy. Nat. Commun., 6, 2015, 7247.
108. [108] Hutton, M., Lendon, C.L., Rizzu, P., Baker, M., Froelich, S., Houlden, H., et al. Association of missense and 5′-splice-site mutations in tau with the inherited dementia FTDP-17. Nature 393:6686 (1998 Jun 18), 702–705.
109. [109] Neudorfer, O., Giladi, N., Elstein, D., Abrahamov, A., Turezkite, T., Aghai, E., et al. Occurrence of Parkinson's syndrome in type I Gaucher disease. QJM 89:9 (1996 Sep), 691–694.
110. [110] Bembi, B., Zambito Marsala, S., Sidransky, E., Ciana, G., Carrozzi, M., Zorzon, M., et al. Gaucher's disease with Parkinson's disease: clinical and pathological aspects. Neurology 61:1 (2003 Jul 8), 99–101.
111. [111] Sidransky, E., Nalls, M.A., Aasly, J.O., Aharon-Peretz, J., Annesi, G., Barbosa, E.R., et al. Multicenter analysis of glucocerebrosidase mutations in Parkinson's disease. N. Engl. J. Med. 361:17 (2009 Oct 22), 1651–1661.
112. [112] Venter, J.C., Adams, M.D., Myers, E.W., Li, P.W., Mural, R.J., Sutton, G.G., et al. The sequence of the human genome. Science 291:5507 (2001 Feb 16), 1304–1351.
113. [113] Lander, E.S., Linton, L.M., Birren, B., Nusbaum, C., Zody, M.C., Baldwin, J., et al. Initial sequencing and analysis of the human genome. Nature 409:6822 (2001 Feb 15), 860–921.
114. [114] International HapMap Consortium. A haplotype map of the human genome. Nature 437:7063 (2005 Oct 27), 1299–1320.
115. [115] International HapMap 3 Consortium, Altshuler, D.M., Gibbs, R.A., Peltonen, L., Altshuler, D.M., Gibbs, R.A., et al. Integrating common and rare genetic variation in diverse human populations. Nature 467:7311 (2010 Sep 2), 52–58.
116. [116] 1000 Genomes Project Consortium. A map of human genome variation from population-scale sequencing. Nature 467:7319 (2010 Oct 28), 1061–1073.
117. [117] Sawcer, S., Bayes factors in complex genetics. Eur. J. Hum. Genet. 18:7 (2010 Jul), 746–750.
118. [118] Fung, H.-C., Scholz, S., Matarin, M., Simón-Sánchez, J., Hernandez, D., Britton, A., et al. Genome-wide genotyping in Parkinson's disease and neurologically normal controls: first stage analysis and public release of data. Lancet Neurol. 5:11 (2006 Nov), 911–916.
119. [119] Maraganore, D.M., de Andrade, M., Lesnick, T.G., Strain, K.J., Farrer, M.J., Rocca, W.A., et al. High-resolution whole-genome association study of Parkinson disease. Am. J. Hum. Genet. 77:5 (2005 Nov), 685–693.
120. [120] Simón-Sánchez, J., Schulte, C., Bras, J.M., Sharma, M., Gibbs, J.R., Berg, D., et al. Genome-wide association study reveals genetic risk underlying Parkinson's disease. Nat. Genet. 41:12 (2009 Dec), 1308–1312.
121. [121] Pankratz, N., Wilk, J.B., Latourelle, J.C., DeStefano, A.L., Halter, C., Pugh, E.W., et al. Genomewide association study for susceptibility genes contributing to familial Parkinson disease. Hum. Genet. 124:6 (2009 Jan), 593–605.
122. [122] Simón-Sánchez, J., van Hilten, J.J., van de Warrenburg, B., Post, B., Berendse, H.W., Arepalli, S., et al. Genome-wide association study confirms extant PD risk loci among the Dutch. Eur. J. Hum. Genet. 19:6 (2011 Jun), 655–661.
123. [123] Spencer, C.C.A., Plagnol, V., Strange, A., Gardner, M., Paisan-Ruiz, C., Band, G., et al. Dissection of the genetics of Parkinson's disease identifies an additional association 5’ of SNCA and multiple associated haplotypes at 17q21. Hum. Mol. Genet. 20:2 (2011 Jan 15), 345–353.
124. [124] Nalls, M.A., Plagnol, V., Hernandez, D.G., Sharma, M., Sheerin, U.-M., Saad, M., et al. Imputation of sequence variants for identification of genetic risks for Parkinson's disease: a meta-analysis of genome-wide association studies. Lancet 377:9766 (2011 Feb 19), 641–649.
125. [125] Pankratz, N., Beecham, G.W., DeStefano, A.L., Dawson, T.M., Doheny, K.F., Factor, S.A., et al. Meta-analysis of Parkinson's disease: identification of a novel locus, RIT2. Ann. Neurol. 71:3 (2012 Mar), 370–384.
126. [126] Hamza, T.H., Zabetian, C.P., Tenesa, A., Laederach, A., Montimurro, J., Yearout, D., et al. Common genetic variation in the HLA region is associated with late-onset sporadic Parkinson's disease. Nat. Genet. 42:9 (2010 Sep), 781–785.
127. [127] Deleidi, M., Gasser, T., The role of inflammation in sporadic and familial Parkinson's disease. Cell Mol. Life Sci. 70:22 (2013 Nov), 4259–4273.
128. [128] Moutsianas, L., Jostins, L., Beecham, A.H., Dilthey, A.T., Xifara, D.K., Ban, M., et al. Class II HLA interactions modulate genetic risk for multiple sclerosis. Nat. Genet. 47:10 (2015 Oct), 1107–1113.
129. [129] Lenz, T.L., Deutsch, A.J., Han, B., Hu, X., Okada, Y., Eyre, S., et al. Widespread non-additive and interaction effects within HLA loci modulate the risk of autoimmune diseases. Nat. Genet. 47:9 (2015 Sep), 1085–1090.
130. [130] Lill, C.M., Recent advances and future challenges in the genetics of multiple sclerosis. Front. Neurol., 5, 2014, 130.
131. [131] Lambert, J.C., Ibrahim-Verbaas, C.A., Harold, D., Naj, A.C., Sims, R., Bellenguez, C., et al. Meta-analysis of 74,046 individuals identifies 11 new susceptibility loci for Alzheimer's disease. Nat. Genet. 45:12 (2013 Dec), 1452–1458.
132. [132] Shi, J., Levinson, D.F., Duan, J., Sanders, A.R., Zheng, Y., Pe'er, I., et al. Common variants on chromosome 6p22.1 are associated with schizophrenia. Nature 460:7256 (2009 Aug 6), 753–757.
133. [133] Mungall, A.J., Palmer, S.A., Sims, S.K., Edwards, C.A., Ashurst, J.L., Wilming, L., et al. The DNA sequence and analysis of human chromosome 6. Nature 425:6960 (2003 Oct 23), 805–811.
134. [134] Pihlstrøm, L., Toft, M., Cumulative genetic risk and age at onset in Parkinson's disease. Mov. Disord., 2015 Aug 3.
135. [135] Brockmann, K., Schulte, C., Hauser, A.-K., Lichtner, P., Huber, H., Maetzler, W., et al. SNCA: major genetic modifier of age at onset of Parkinson's disease. Mov. Disord. 28:9 (2013 Aug), 1217–1221.
136. [136] Lill, C.M., Hansen, J., Olsen, J.H., Binder, H., Ritz, B., Bertram, L., Impact of Parkinson's disease risk loci on age at onset. Mov. Disord 30:6 (2015 May), 847–850.
137. [137] Nalls, M.A., Escott-Price, V., Williams, N.M., Lubbe, S., Keller, M.F., Morris, H.R., et al. Genetic risk and age in Parkinson's disease: continuum not stratum. Mov. Disord. 30:6 (2015 May), 850–854.
138. [138] Davis, A.A., Andruska, K.M., Benitez, B.A., Racette, B.A., Perlmutter, J.S., Cruchaga, C., Variants in GBA, SNCA, and MAPT influence Parkinson disease risk, age at onset, and progression. Neurobiol. Aging, 37, 2016 Jan 209.e1-7.
139. [139] Hamza, T.H., Chen, H., Hill-Burns, E.M., Rhodes, S.L., Montimurro, J., Kay, D.M., et al. Genome-wide gene-environment study identifies glutamate receptor gene GRIN2A as a Parkinson's disease modifier gene via interaction with coffee. PLoS Genet., 7(8), 2011 Aug, e1002237.
140. [140] Ahmed, I., Lee, P.-C., Lill, C.M., Searles Nielsen, S., Artaud, F., Gallagher, L.G., et al. Lack of replication of the GRIN2A-by-coffee interaction in Parkinson disease. PLoS Genet., 10(11), 2014 Nov, e1004788.
141. [141] Hill-Burns, E.M., Singh, N., Ganguly, P., Hamza, T.H., Montimurro, J., Kay, D.M., et al. A genetic basis for the variable effect of smoking/nicotine on Parkinson's disease. Pharmacogenomics J. 13:6 (2013 Dec), 530–537.
142. [142] Lunnon, K., Smith, R., Hannon, E., De Jager, P.L., Srivastava, G., Volta, M., et al. Methylomic profiling implicates cortical deregulation of ANK1 in Alzheimer's disease. Nat. Neurosci. 17:9 (2014 Sep), 1164–1170.
143. [143] De Jager, P.L., Srivastava, G., Lunnon, K., Burgess, J., Schalkwyk, L.C., Yu, L., et al. Alzheimer's disease: early alterations in brain DNA methylation at ANK1, BIN1, RHBDF2 and other loci. Nat. Neurosci. 17:9 (2014 Sep), 1156–1163.
144. [144] Lill, C.M., Bertram, L., Probing the epigenome by EWAS: a new era in brain disease research. Mov. Disord., 30(2), 2015 Feb, 197.